Skip to main content
Equibles
CNTB logo

CNTB · Connect Biopharma Holdings Ltd · Metrics

Track CNTB — free

Use CNTB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNTB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 +0.03 (+3.62%) Q2 2022 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$53.06M
Shares
62.97M
Volume · Oct 27 570.81K Avg daily vol (3M) 3.89M

CNTB metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.84
Market cap
$53.06M

Price action

20 metrics
Price change (1W)
-3.7%
Price change (30D)
-22.0%
Price change (3M)
-59.5%
Price change (6M)
-64.9%
Price change (YTD)
-70.1%
Price change (1Y)
-47.3%
Trailing year
Price change (5Y)
-94.9%
52-week high
$3.69
52-week low
$0.76
Change from 52-week high
-77.2%
Change from 52-week low
+10.5%
Annualized volatility
101.6%
Annualized volatility (3M)
122.5%
Beta
0.5
RSI (14D)
35.2
Price vs SMA 50
-42.0%
Price vs SMA 200
-61.9%
Avg volume (3M)
3.89M
Relative volume
0.2
Average dollar volume
$4.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
62.97M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.3×
reciprocal yield 13.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
18.0×
reciprocal yield 5.6%
P / book
2.0
reciprocal yield 50.6%
FCF yield
-114.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-130.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
160.6×
reciprocal yield 0.6%
EV / revenue historical average (5Y)
160.6×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-06-30

Profitability

9 metrics
Gross margin
—
Operating margin
-2,384.5%
Trailing 12 months
Net margin
-2,336.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$70.41M
Net income (TTM)
−$68.99M
Trailing 12 months
Diluted EPS (TTM)
$-1.19
FCF margin
-2,053.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.05
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.22
EBITDA per diluted share (TTM)
$-1.21
Net income per diluted share (TTM)
$-1.20
Operating cash flow per diluted share (TTM)
$-1.05
Free cash flow per diluted share (TTM)
$-1.05
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.93
Stock compensation per diluted share (TTM)
$0.07
Book value per share
$0.74

Growth

11 metrics
Revenue growth YoY
+5,666.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.95M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+13.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-256.8%
Return on assets
-158.7%
Debt / equity
0.0
Current ratio
2.4
EBITDA (TTM)
−$69.73M
Free cash flow (TTM)
−$60.63M
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$31.49M
Latest balance sheet
Cash & equivalents
$27.02M
Total assets
$43.47M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$60.58M
Capital expenditures (TTM)
$50,000
R&D (TTM)
$53.70M
SG&A (TTM)
—
Stock compensation (TTM)
$4.29M
R&D / revenue
1,818.3%
Stock compensation / revenue
145.4%

Ownership (13F)

9 metrics
13F filers
55
13F filer change QoQ
+15
Institutional ownership
22.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
17.5%
Private-fund adviser ownership
17.3%
Active holders' share change QoQ
-1.3%
Holder tenure
2.6
Price vs estimated holder cost
+3.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
6.1%
Latest settlement · 1.7 days to cover
Days to cover
1.7d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1835268 CUSIP G23549101 13F (30d) 7 filings 7 filers Visit website Investor relations